Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,841 to 1,860 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genome composition and genetic characterization of SARS-CoV-2. | Saudi J Biol Sci | 2021 | 33519278 | PubTator, text mining | PubMed |
| Latent periodicity-2 in coronavirus SARS-CoV-2 genome: Evolutionary implications. | J Theor Biol | 2021 | 33508323 | PubTator, text mining | PubMed |
| Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. | J Gen Virol | 2021 | 33507143 | PubTator, text mining | PubMed |
| Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. | Viruses | 2021 | 33503819 | PubTator, text mining | PubMed |
| Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors. | Viruses | 2021 | 33498923 | PubTator, text mining | PubMed |
| The COVID-19 pandemic face mask waste: A blooming threat to the marine environment. | Chemosphere | 2021 | 33497928 | PubTator, text mining | PubMed |
| Peptide enzyme-linked immunosorbent assay (pELISA) as a possible alternative to the neutralization test for evaluating the immune response to IBV vaccine. | BMC Vet Res | 2021 | 33494765 | PubTator, text mining | PubMed |
| Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. | J Genet Eng Biotechnol | 2021 | 33492492 | PubTator, text mining | PubMed |
| Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. | Heliyon | 2021 | 33490695 | PubTator, text mining | PubMed |
| SARS-COV-2 infection and lung tumor microenvironment. | Mol Biol Rep | 2021 | 33486674 | PubTator, text mining | PubMed |
| The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. | Eur J Med Chem | 2021 | 33486200 | PubTator, text mining | PubMed |
| Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2. | Biochimie | 2021 | 33484784 | PubTator, text mining | PubMed |
| Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. | Biochem Pharmacol | 2021 | 33482149 | PubTator, text mining | PubMed |
| SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. | Membranes (Basel) | 2021 | 33477477 | PubTator, text mining | PubMed |
| Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs. | Infect Genet Evol | 2021 | 33476804 | PubTator, text mining | PubMed |
| Coronavirus replication-transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. | Proc Natl Acad Sci U S A | 2021 | 33472860 | PubTator, text mining | PubMed |
| Impact of WIN site inhibitor on the WDR5 interactome. | Cell Rep | 2021 | 33472061 | PubTator, text mining | PubMed |
| At Least Seven Distinct Rotavirus Genotype Constellations in Bats with Evidence of Reassortment and Zoonotic Transmissions. | mBio | 2021 | 33468689 | PubTator, text mining | PubMed |
| Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors. | mBio | 2021 | 33468688 | PubTator, text mining | PubMed |
| The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. | Arch Virol | 2021 | 33462671 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=93